Research is being conducted on the effectiveness of the BNT162b2 vaccine against omicron in children aged 5 to 11 years. Studies are examining vaccine effectiveness in various locations, including the US, Malaysia, and Hong Kong, with some focusing on specific outcomes such as hospitalization or asymptomatic infection. The scope of the research also extends to adolescents and includes comparisons with other vaccines, such as CoronaVac.